ONCAlert | Upfront Therapy for mRCC

Mantle Cell Lymphoma VIEW MORE >>

Salvage therapy with high‐dose cyclophosphamide showed meaningful clinical activity in a cohort of 6 patients with mantle cell lymphoma who were previously treated with ≥2 prior lines of therapy and had no other available options. These patients made up 14% of the 42 participants in a phase II study showing similar efficacy in adult patients with other relapsed or refractory B‐cell non‐Hodgkin lymphomas.

Latest JournalAll Journals >>

Evolving Paradigms Mantle Cell Lymphoma
Evolving Paradigms
MORE >>

The Targeted Oncology mantle cell lymphoma resource center serves as a hub for all clinical news and expert insights related to this rare subtype of non-Hodgkin lymphoma. Content found here includes video interviews with lymphoma experts and key opinion leaders in the field sharing their perspectives on existing mantle cell lymphoma treatment options and management approaches, including case studies that describe the clinical presentation and diagnostic criteria for patients with MCL.

This page also houses the most recent issue of Evolving Paradigms: Mantle Cell Lymphoma. This educational journal offers information regarding mantle cell lymphoma prognosis, staging, and risk, as well as current and emerging therapies for the disease.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.